Citius Oncology (CTOR) Competitors

Citius Oncology (NASDAQ:CTOR) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends, valuation and community ranking.

Do insiders and institutionals hold more shares of CTOR or AVIR?

70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 4.6% of Citius Oncology shares are owned by insiders. Comparatively, 18.1% of Atea Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Does the media refer more to CTOR or AVIR?

In the previous week, Atea Pharmaceuticals had 2 more articles in the media than Citius Oncology. MarketBeat recorded 4 mentions for Atea Pharmaceuticals and 2 mentions for Citius Oncology. Atea Pharmaceuticals' average media sentiment score of 0.59 beat Citius Oncology's score of 0.20 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Citius Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atea Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer CTOR or AVIR?

Atea Pharmaceuticals received 18 more outperform votes than Citius Oncology when rated by MarketBeat users. However, 50.00% of users gave Citius Oncology an outperform vote while only 46.34% of users gave Atea Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Citius Oncology	Outperform Votes 1 50.00%	Underperform Votes 1 50.00%
Atea Pharmaceuticals	Outperform Votes 19 46.34%	Underperform Votes 22 53.66%

Which has better earnings & valuation, CTOR or AVIR?

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$21.15M	N/A	N/A
Atea Pharmaceuticals	N/A	N/A	-$135.96M	-$1.65	-1.76

Do analysts prefer CTOR or AVIR?

Citius Oncology currently has a consensus price target of $3.00, indicating a potential upside of 229.67%. Atea Pharmaceuticals has a consensus price target of $6.00, indicating a potential upside of 106.90%. Given Citius Oncology's higher probable upside, analysts clearly believe Citius Oncology is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Atea Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Is CTOR or AVIR more profitable?

Atea Pharmaceuticals' return on equity of -34.90% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-43.67%	-9.74%
Atea Pharmaceuticals	N/A	-34.90%	-32.38%

Which has more volatility and risk, CTOR or AVIR?

Citius Oncology has a beta of -0.17, indicating that its stock price is 117% less volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500.

Summary

Atea Pharmaceuticals beats Citius Oncology on 9 of the 13 factors compared between the two stocks.